Malaysia
Search
Sign In
Change Password
Points
Sign Out
Endocrinology
Top Medical News
Preconception treatment with levothyroxine fails to bring significantly better cognitive outcomes in children up to age 2 years compared with treatment initiated at 8–14 weeks of gestation, a study has found.
There is not enough irrefutable evidence that dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists have positive effects on cognition in patients with type 2 diabetes mellitus (T2DM), according to a study.
A comprehensive toolkit tailored to arming primary care physicians (PCPs) with practical resources to help them identify, assess, and manage those at risk of fractures has recently been launched by the Asia Pacific Fragility Fracture Alliance (APFFA).
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Long-term use of antibiotic may put women at increased risk of type 2 diabetes, a study suggests.
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.
Special Reports
The most recent report by the National Health and Morbidity
Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with
consistent, unrelenting efforts by stakeholders and policymakers, the figures
for NCDs continue to climb.
MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in
the country and to obtain his thoughts on the ramifications of the findings.
In this final issue of our series, join us as we
look into the upcoming results of the pivotal EMPEROR trials, which will
investigate the use of empagliflozin in patients with either preserved or
reduced ejection fraction heart failure, with or without type 2 diabetes.
Understand why heart failure has such a high clinical burden, and the great
unmet need in providing solutions for it.
In this fourth issue,
join us as we discover the unique biology Asians have with respect to diabetes.
Take a closer look at trials evaluating whether empagliflozin’s cardiovascular
and renal benefits – as analysed in Asians – are consistent with the overall
trial population, and how it addresses unmet needs.
At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.
_1_2_Square.jpg)
Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.
In this third issue we take
a look at how empagliflozin made a bold impact on clinical guidelines across
multiple specialties. We will explore how existing treatment recommendations
were altered, and summarise the current guidelines and future perspectives of
empagliflozin’s use.
This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
possible
mechanisms for its cardiovascular benefits.
Conference Reports
Imposing health warnings on sugary drinks may improve drink selection choices, according to a meta-analysis presented at Nutrition 2020 Live Online.
Increased video game use may be linked to poorer dietary habits and reduced physical activity in college-aged men, according to a study presented at Nutrition 2020 Live Online.
Patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) do not have a higher risk of major adverse cardiovascular events (MACE) with ertugliflozin, according to results of the phase III VERTIS CV* trial.
About one-quarter of the calories consumed by children and adolescents may be acquired from empty calories, according to a US-based study presented at Nutrition 2020 Live Online.
The efficacy and cardiovascular (CV) safety of the SGLT2* inhibitor empagliflozin vs DPP-4** inhibitors and GLP-1*** receptor agonists in real-world patients were demonstrated in two interim analyses of the EMPRISE+ study presented at ADA 2020.
Women with a history of gestational diabetes were 50 percent more likely to have a short interval between pregnancies compared to women without the condition, suggests a new study.
Dapagliflozin reduced the incidence of new-onset type 2 diabetes (T2D) in patients with heart failure and reduced ejection fraction (HFrEF), according to a prespecified exploratory analysis of the DAPA-HF* trial.
Multimedia
